Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Thematic (Sector/Industry)

<ul>
<li>On 20th March 2026, the critical patent for Semaglutide expires in India, decisively ending the innovator's legal monopoly and enabling highly affordable generic versions. </li>
<li>This triggers a massive 70% retail price drop in India, exponentially expanding affordable access to millions suffering from prevalent obesity and diabetes.</li>
<li>Vertically integrated formulators like Sun Pharma and specialized API manufacturers like Divis Laboratories capture maximum alpha through scaled volumes and zero customer acquisition costs.</li>
</ul>


On 20th March 2026, the critical patent for Semaglutide expires in India, decisively ending the innovator's legal monopoly and enabling highly affordable generic versions. 
This triggers a massive 70% retail price drop in India, exponentially expanding affordable access to millions suffering from prevalent obesity and diabetes.
Vertically integrated formulators like Sun Pharma and specialized API manufacturers like Divis Laboratories capture maximum alpha through scaled volumes and zero customer acquisition costs.


The GLP-1 Super-Cycle: Deconstructing India’s 2026 Patent Cliff and Alpha Generators

<ul>
<li>India's CDMOs are tripling capacity and pivoting to peptides, ADCs, and drug-device combinations as global pharma outsources complex drug development.</li>
<li>The GLP-1 boom, BIOSECURE Act, and a $64 billion addressable market are redirecting multi-year manufacturing mandates toward Indian CRDMO platforms.</li>
<li>Firms investing in science-led infrastructure will command structurally higher margins, those adding only volume face commoditisation and multiple compression ahead.</li>
</ul>


India's CDMOs are tripling capacity and pivoting to peptides, ADCs, and drug-device combinations as global pharma outsources complex drug development.
The GLP-1 boom, BIOSECURE Act, and a $64 billion addressable market are redirecting multi-year manufacturing mandates toward Indian CRDMO platforms.
Firms investing in science-led infrastructure will command structurally higher margins, those adding only volume face commoditisation and multiple compression ahead.


The CDMO Arms Race: How India Is Quietly Becoming the World's Drug Factory

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass).</li>
<li>We will maintain our bullish view as long as market dynamics remain healthy and the SPX and ACWI-US are above 5700-5785 and $120-$121 (up from 5500 and $115).</li>
<li>We are upgrading Korea(KOSPI) to overweight; we discussed May 30 several Financials and other stocks to buy. KOSPI has exploded higher since, and is now reversing its 2-year RS downtrend.</li>
</ul>


We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass).
We will maintain our bullish view as long as market dynamics remain healthy and the SPX and ACWI-US are above 5700-5785 and $120-$121 (up from 5500 and $115).
We are upgrading Korea(KOSPI) to overweight; we discussed May 30 several Financials and other stocks to buy. KOSPI has exploded higher since, and is now reversing its 2-year RS downtrend.


Upgrading Korea to Overweight; MSCI ACWI and Emerging Market Breakouts

<ul>
<li>India's pharma landscape is gearing up for a seismic shift as Semaglutide, used in diabetes and obesity, faces patent expiry in India by March 2026.</li>
<li>With the global Semaglutide market expected to hit $56.75 billion by 2030, India’s low obesity drug penetration and cost-sensitive population make it a high-potential, underpenetrated market. </li>
<li>The Semaglutide opportunity could rival Revlimid for Indian players. Natco, with FTF in the US. Expect multi-year growth runway, but execution, supply chain complexity, and regulatory hurdles remain key monitorables.</li>
</ul>


India's pharma landscape is gearing up for a seismic shift as Semaglutide, used in diabetes and obesity, faces patent expiry in India by March 2026.
With the global Semaglutide market expected to hit $56.75 billion by 2030, India’s low obesity drug penetration and cost-sensitive population make it a high-potential, underpenetrated market. 
The Semaglutide opportunity could rival Revlimid for Indian players. Natco, with FTF in the US. Expect multi-year growth runway, but execution, supply chain complexity, and regulatory hurdles remain key monitorables.


Semaglutide Patent Expiry: The Next Big Unlock in Global Pharma

Event-Driven

OneSource Specialty Pharma / Event-Driven

<ul>
<li>OneSource Specialty Pharma has approved a Composite Scheme of Arrangement to acquire Steriscience's EuropeanCDMO and Brooks Steriscience’s Indian anti-infective assets. 
</li>
<li>The transaction adds approximately $107 million in projected FY27 revenue, significantly diversifying the portfolio, reducing single-site risk, raising the consolidated FY28 revenue outlook to over $500 million.</li>
<li>While the acquisition multiples appear steep for subscale assets, if management successfully delivers on ambitious growth targets, the transaction could position OneSource among the most competitive players in CDMO landspace.</li>
</ul>


OneSource Specialty Pharma has approved a Composite Scheme of Arrangement to acquire Steriscience's EuropeanCDMO and Brooks Steriscience’s Indian anti-infective assets. 

The transaction adds approximately $107 million in projected FY27 revenue, significantly diversifying the portfolio, reducing single-site risk, raising the consolidated FY28 revenue outlook to over $500 million.
While the acquisition multiples appear steep for subscale assets, if management successfully delivers on ambitious growth targets, the transaction could position OneSource among the most competitive players in CDMO landspace.


Decoding OneSource Pharma’s Strategic Amalgamation: A Blueprint for a Global CDMO Powerhouse?

India

OneSource Specialty Pharma is an India-based contract development and manufacturing organization (CDMO) specializing in biological drug products, complex sterile injectables, drug-device combinations, and soft gelatin capsules. The company offers end-to-end CDMO services from early-stage development to commercial supply for pharmaceutical and biotech partners globally. It was founded in 2007 and is headquartered in Bengaluru, India.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

OneSource Specialty Pharma (ONESOURC IN)

The GLP-1 Super-Cycle: Deconstructing India’s 2026 Patent Cliff and Alpha Generators

Semaglutide patent expiration in India leads to 70% price drop, increasing access to affordable generic versions for obesity and diabetes treatment.

Nimish Maheshwari

The CDMO Arms Race: How India Is Quietly Becoming the World's Drug Factory

Indian CDMOs are expanding capacity and shifting focus to complex drug development, with potential for higher margins in the evolving...

Nimish Maheshwari

Upgrading Korea to Overweight; MSCI ACWI and Emerging Market Breakouts

MSCI $ACWI and Emerging Market $EEM Breakouts; Upgrading Korea $EWY to Overweight; Downgrading Broad Europe, but staying Overweight Germany,...

Vermilion Research

Semaglutide Patent Expiry: The Next Big Unlock in Global Pharma

India's pharma industry prepares for Semaglutide patent expiry in 2026, offering a high-potential market opportunity for Indian players like Natco...

Nimish Maheshwari

Decoding OneSource Pharma’s Strategic Amalgamation: A Blueprint for a Global CDMO Powerhouse?

OneSource Specialty Pharma to acquire Steriscience's European CDMO and Brooks Steriscience's Indian anti-infective assets positioning as a...

Nimish Maheshwari

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

The GLP-1 Super-Cycle: Deconstructing India’s 2026 Patent Cliff and Alpha Generators

​Semaglutide patent expiration in India leads to 70% price drop, increasing access to affordable generic versions for obesity and diabetes treatment.

Nimish Maheshwari

The CDMO Arms Race: How India Is Quietly Becoming the World's Drug Factory

​Indian CDMOs are expanding capacity and shifting focus to complex drug development, with potential for higher margins in the evolving...

Nimish Maheshwari

Upgrading Korea to Overweight; MSCI ACWI and Emerging Market Breakouts

MSCI $ACWI and Emerging Market $EEM Breakouts; Upgrading Korea $EWY to Overweight; Downgrading Broad Europe, but staying Overweight Germany,...

Vermilion Research

Semaglutide Patent Expiry: The Next Big Unlock in Global Pharma

​India's pharma industry prepares for Semaglutide patent expiry in 2026, offering a high-potential market opportunity for Indian players like Natco...

Nimish Maheshwari

Decoding OneSource Pharma’s Strategic Amalgamation: A Blueprint for a Global CDMO Powerhouse?

​OneSource Specialty Pharma to acquire Steriscience's European CDMO and Brooks Steriscience's Indian anti-infective assets positioning as a...

Nimish Maheshwari

Semaglutide patent expiration in India leads to 70% price drop, increasing access to affordable generic versions for obesity and diabetes treatment.

Indian CDMOs are expanding capacity and shifting focus to complex drug development, with potential for higher margins in the evolving...

India's pharma industry prepares for Semaglutide patent expiry in 2026, offering a high-potential market opportunity for Indian players like Natco...

OneSource Specialty Pharma to acquire Steriscience's European CDMO and Brooks Steriscience's Indian anti-infective assets positioning as a...